160 related articles for article (PubMed ID: 6396766)
1. Current results of the University of Arizona Adjuvant Breast Cancer trials (1974-1984).
Jones SE; Brooks RJ; Takasugi BJ; Garewal HS; Giordano GF; Ketchel SJ; Jackson R; Heusinkveld RS; Kemmer SR; Moon TE
Recent Results Cancer Res; 1984; 96():133-40. PubMed ID: 6396766
[No Abstract] [Full Text] [Related]
2. The use of a natural history data base to compare outcome among several trials of adjuvant chemotherapy for stage II breast cancer.
Jones SE; Moon TE
Recent Results Cancer Res; 1984; 96():148-54. PubMed ID: 6396768
[No Abstract] [Full Text] [Related]
3. Adjuvant therapy of breast cancer: a Southwest Oncology Group experience.
Rivkin SE; Glucksberg H; Foulkes M
Recent Results Cancer Res; 1984; 96():166-74. PubMed ID: 6396770
[No Abstract] [Full Text] [Related]
4. Adjuvant programs for postmenopausal women with node-positive breast cancer: preliminary analysis of 5-year results.
Rossi A; Brambilla C; Valagussa P; Bonadonna G
Recent Results Cancer Res; 1984; 96():178-83. PubMed ID: 6396772
[No Abstract] [Full Text] [Related]
5. A controlled trial of adjuvant chemotherapy with melphalan versus cyclophosphamide, methotrexate, and fluorouracil for breast cancer.
Howell A; Rubens RD; Bush H; George WD; Howat JM; Crowther D; Sellwood RA; Hayward JL; Knight RK; Bulbrook RD
Recent Results Cancer Res; 1984; 96():74-89. PubMed ID: 6396780
[No Abstract] [Full Text] [Related]
6. Adriamycin, vincristine, cyclophosphamide and 5-fluorouracil (AVCF) compared with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in premenopausal breast carcinoma. Personal results.
Mathé G; Misset JL; Plagne R; Reizenstein P; Belpomme D; Le Mevel B; Guerrin J; Fumoleau P; Metz R; Delgado M
Drugs Exp Clin Res; 1986; 12(1-3):143-5. PubMed ID: 3525068
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy of breast cancer: a promising experiment or standard practice?
Henderson IC
J Clin Oncol; 1985 Feb; 3(2):140-3. PubMed ID: 3881560
[No Abstract] [Full Text] [Related]
8. Adjuvant systemic therapy in postoperative node-positive patients with breast carcinoma: the CALGB trial and the ECOG premenopausal trial.
Tormey C
Recent Results Cancer Res; 1984; 96():155-65. PubMed ID: 6396769
[No Abstract] [Full Text] [Related]
9. Significance of drug dose, timing and radiotherapy in adjuvant therapy of breast cancer.
Buzdar AU; Smith TL; Marcus CE; Hortobagyi GN; Blumenschein GR
Recent Results Cancer Res; 1984; 96():141-7. PubMed ID: 6396767
[No Abstract] [Full Text] [Related]
10. Review: experience of randomized trials without surgical controls.
Tormey DC
Recent Results Cancer Res; 1984; 96():184-7. PubMed ID: 6396773
[No Abstract] [Full Text] [Related]
11. [Chemotherapy using the CMF regimen (cyclophosphamide, methotrexate, and 5-fluorouracil) and the VAC protocol (vincristine, adriamycin and cyclophosphamide) in patients with advanced breast cancer].
Glińska H; Zulichowska J; Radziszewska J; Sukiennik-Siuda M; Trabka E
Nowotwory; 1987; 37(3):251-61. PubMed ID: 3438177
[No Abstract] [Full Text] [Related]
12. Clinical trials referral resource. Adjuvant therapy of breast cancer.
Cheson BD
Oncology (Williston Park); 1989 Jun; 3(6):70-1, 74-5, 78. PubMed ID: 2534915
[No Abstract] [Full Text] [Related]
13. Chemotherapy with mitomycin-C, epidoxorubicin and vinblastine in CMF failing breast cancer patients.
Pronzato P; Amoroso D; Bertelli G; Queirolo P; Sertoli MR; Rosso R
Anticancer Res; 1990; 10(6):1743-5. PubMed ID: 2126683
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy for node-negative breast cancer patients.
Bonadonna G; Zambetti M; Valagussa P
Recent Results Cancer Res; 1989; 115():175-9. PubMed ID: 2516350
[No Abstract] [Full Text] [Related]
15. CMF adjuvant programs at the Milan Cancer Institute.
Bonadonna G; Rossi A; Tancini G; Valagussa P; Veronesi U
Recent Results Cancer Res; 1984; 96():66-73. PubMed ID: 6549356
[No Abstract] [Full Text] [Related]
16. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
Misset JL; di Palma M; Delgado M; Plagne R; Chollet P; Fumoleau P; Le Mevel B; Belpomme D; Guerrin J; Fargeot P; Metz R; Ithzaki M; Hill C; Mathé G
J Clin Oncol; 1996 Apr; 14(4):1136-45. PubMed ID: 8648368
[TBL] [Abstract][Full Text] [Related]
17. Maintenance tamoxifen after induction postoperative chemotherapy in node-positive breast cancer patients: the Eastern Cooperative Oncology Group Trials.
Tormey DC; Gray R; Falkson HC; Gilchrist K; Abeloff MD; Falkson G
Recent Results Cancer Res; 1993; 127():185-96. PubMed ID: 8502815
[No Abstract] [Full Text] [Related]
18. FAC + BCG as adjuvant therapy in breast cancer: an 8-year update.
Blumenschein GR; Buzdar AU; Hortobagyi GN
Recent Results Cancer Res; 1984; 96():129-32. PubMed ID: 6528087
[No Abstract] [Full Text] [Related]
19. Adjuvant chemotherapy in high-risk breast cancer patients with ten or more positive lymph nodes.
Jaiyesimi IA; Buzdar AU
Am J Clin Oncol; 1992 Apr; 15(2):180-3. PubMed ID: 1313203
[No Abstract] [Full Text] [Related]
20. Clinical trials in advanced breast cancer.
Schwartsmann G; Pinedo HM
Eur J Cancer Clin Oncol; 1987 Jun; 23(6):595-7. PubMed ID: 3653182
[No Abstract] [Full Text] [Related]
[Next] [New Search]
